Through its impact on intestinal dysbiosis, ACE2 imbalance have been linked to poor outcomes (including higher disease severity and mortality rate) in COVID-19 patients with pre-existing age-related comorbidities (102). This evidence concerns the gene ACE2 and COVID-19.